• No results found

Development and Validation of a Screening Questionnaire for Psoriatic Arthritis

N/A
N/A
Protected

Academic year: 2021

Share "Development and Validation of a Screening Questionnaire for Psoriatic Arthritis"

Copied!
21
0
0

Loading.... (view fulltext now)

Full text

(1)

Development and

Validation of a

Screening Questionnaire

for

Psoriatic Arthritis

Dafna D. Gladman

1

, Catherine T. Schentag

1

, Brian

D. Tom

2

, Vinod Chandran

1

, Cheryl F. Rosen

1

Vernon T. Farewell

2

1

University of Toronto, Canada and

2

MRC Biostatistics Unit, Cambridge, UK

(2)

The CASPAR criteria for the

classification of PsA should be helpful in

diagnosing the disease

High sensitivity and specificity in early PsA

»

Chandran V, et al. Arthritis Rheum 2006:54(S9):S717

High sensitivity and specificity in family

medicine

»

Chandran V, et al Arthritis Rheum 2006:54: 4091

However, an assessment by a physician

to document inflammatory arthritis is

necessary

Toronto Psoriatic Arthritis Screening

questionnaire (ToPAS)

(3)

In certain clinical and

epidemiological settings it is

impossible to have all patients

reviewed by a physician

Therefore, a screening tool to

identify patients who may have PsA

is necessary

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(4)

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

To develop and validate a

screening questionnaire to

identify patients with a high

likelihood of having PsA for use

in clinical settings and

epidemiological studies

(5)

Methods

Development of ToPAS

Review of symptoms and signs seen

among patients with PsA

Evaluation of the questionnaire by:

»

Patients with PsA

»

Patients attending a rheumatology clinic

»

Rheumatologists, dermatologists,

epidemiologists, scientists

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(6)

The Psoriatic Arthritis Clinic, Centre for Prognosis Studies in The Rheumataic Diseases

Toronto Western Hospital, University Health Network, University of Toronto July 1999

Study # ____

Toronto Psoriatic Arthritis Screening Questionnaire

Date:_ _/_ _/_ _yr mo da

Please tick ( ) each correct response or fill in the blank for all questions on both sides of the page Date of Birth :_ _/_ _/_ _ Gender o Male Ethnic Background:

yr mo da o Female

Figure 1

Skin rash on the elbows Figure 2Pits in the nail

Figure 3

Lifting of the nail

O Yes O No ______ years old

4. Has a doctor ever diagnosed you with psoriasis?

If YES a. At approximately what age did you first notice this skin rash?

O Yes O No

3. Have you ever seen a doctor about a skin rash?

O Yes O No O Yes O No ______ years old O Yes O No

2. Have you ever noticed any of these changes in your fingernails

a. Pits in the nails as shown in figure 2

b. Lifting of the nail from the nail bed as shown in figure 3?

If YES a. At approximately what age did you first notice them? b. Do you have either of these nail changes now?

O Yes O No ______ years old O Yes O No

1a. Have you ever had a skin rash consisting of red AND silvery-white scaly areas particularly on the elbows, knees or scalp as shown in FIGURE 1?

If YES b. At approximately what age did you first notice this skin rash? c. Do you have this rash now?

(7)

O Yes O No ______ years old O Yes O No

9. Have you ever had a skin rash on any part of your body at the same time as joint pain, joint stiffness or swollen red joints?

If YES a. At approximately what age did you first notice this skin rash? b. Do you have this rash now?

O Yes O No O Yes O No O Yes O No

8. Have you ever had back pain lasting at least 3 months that was not injury related?

If YES a. Was the back pain accompanied by stiffness? b. Do you have any back pain now?

O Yes O No O O O O O O O

11. Have you ever been diagnosed with any form of arthritis other than psoriatic arthritis? Rheumatoid arthritis Osteoarthritis Lupus (SLE) Fibromyalgia Ankylosing spondylitis Scleroderrma Other O Yes O No ______ years old

12. Has a doctor ever diagnosed you with psoriatic arthritis?

If Yes a. At what age were your first diagnosed?

O Yes O No

10. Have your ever seen a doctor about any joint pain?

O Yes O No O Yes O No O Yes O No

7. Have you ever had neck pain lasting at least 3 months that was not injury related?

If YES a. Was the neck pain accompanied by stiffness? b. Do you have any neck pain now?

O Yes O No

6. Have you ever had a “sausage shaped” swollen finger or toe that was not the result of an injury?

O Yes O No ______ years old O Yes O No

5a. Have you ever had joint pain, joint stiffness or swollen red joints that was not the results of Injury?

If YES a. At approximately what age did you first notice these symptoms? b. Do you have any symptoms now?

(8)

Testing ToPAS

ToPAS was administered to

consecutive consenting patients

attending 5 different clinics:

1.

The University of Toronto PsA clinic

2.

A psoriasis phototherapy centre

3.

A general dermatology clinic

4.

A general rheumatology clinic (excluding

PsA patients)

5.

A family medicine clinic

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(9)

Confirming the diagnosis of PsA

Patients who completed ToPAS were

assessed by a rheumatologist

»

Standard protocol

»

Complete history, physical examination, and where

appropriate, radiographic assessment.

Based on the protocol the rheumatologist

diagnosed a patient with PsA if they had an

inflammatory arthritis in the presence of

psoriasis

CASPAR criteria were applied

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(10)

A three-step analysis strategy was adopted

1.

A stepwise logistic regression to identify a model with

the questions considered to be most important in

discriminating between those who were diagnosed

with PsA and those who were not

2.

A logistic model was fitted to three clinically relevant

domains for identifying PsA suggested from step 1:

the skin, joints, and nails

3.

A simple weighting of each of the domains used in

step 2 was considered.

»

ROC curves obtained at each step

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(11)

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

178

135

118

123

134

Total

3 ( 1.7)

Family medicine

0 ( 0)

Rheumatology

2 ( 1.7)

Dermatology

39 (24.4)

Psoriasis clinic

134 (100)

PsA clinic

PsA Dx (%)

Group

Results

(12)

572.73 (469)

192.62

Residual variance (df)

AIC

<0.0001

0.060

0.051

<0.0001

0.001

<0.0001

0.060

0.001

0.002

1.08

0.54

0.43

0.54

0.94

0.40

0.41

0.70

0.43

-8.56

1.02

0.84

2.53

3.05

1.89

0.77

2.34

-1.36

Intercept

Skin rash

Pits

Diagnosed Ps

Joint pain

Sausage digit

Back pain

Seen MD

Other Dx

P value

Standard

error

Estimate

O

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(13)

0.0 0.2 0.4 0.6 0.8 1.0 0. 0 0. 2 0. 4 0. 6 0. 8 1. 0 1-Specificity S en si ti vi ty

Cut point 7.71

Sens: 94.2%

Spec: 91.5%

PV+: 81.6%

PV-: 97.5%

ROC Curve for initial logistic regression model

(14)

Pits in nails or Lifting of nail

(Yes or no: Yes =1, No = 0)

Nail Domain

Neck and back pain questions did not improve model (p = 0.46)

Joint pain + Sausage digit + Seen doctor

about joint pain

(Count of ‘yes’ answers: Range 0-3)

Joint Domain

Skin rash + Seen doctor about skin rash

+ Psoriasis Dx

(Count of ‘yes’ answers: Range 0-3)

Skin Domain

Definition

Variable

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(15)

0.0 0.2 0.4 0.6 0.8 1.0 0. 0 0. 2 0. 4 0. 6 0. 8 1. 0 1-Specificity S en si tiv ity

Cut point 7.76

Sens: 90.3%

Spec: 90.5%

PV+: 78.9%

PV-: 96.2%

ROC Curve based on Domains

(16)

Simplified weighting based on

logistic regression

Joints = 2, Skin = 1, Nail = 1

Discriminatory score:

2x (Joint domain variable) +

1x (Skin domain variable) +

1x (Nail domain variable)

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(17)

0.0 0.2 0.4 0.6 0.8 1.0 0. 0 0. 2 0. 4 0. 6 0. 8 1. 0 1-Specificity S en si tiv ity

AUC: 0.954

Cutpoint 8

Sens: 86.8%

Spec: 93.1%

PV+: 83.0%

PV-: 94.8%

(18)

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

100%

90.4% (83.9, 94.5)

Family medicine

* Each grouped with PsA

85.7% (76.9, 91.5)

92.6% (86.4, 96.1)

Rheumatology

95.2% (88.0, 98.2)

91.9% (85,7, 95.6)

Dermatology

86.3% (76.4, 92.5)

89.1% (89.1, 93.2)

Psoriasis

Specificity (95% CI)

Sensitivity (95% CI)

Patient groups*

(19)

ToPAS was derived from features of PsA

and input from patients and investigators

ToPAS is simple, only 12 questions

The simplified index derived ToPAS

proved highly sensitive and specific in 4

groups of patients

Psoriasis

General dermatology

General rheumatology

Family medicine

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(20)

Our simplified index derived from the

ToPAS is very good at identifying those

who are diagnosed with PsA and those

who are not

This instrument is now ready for further

validation

It should be tested in other centers to

confirm its usefulness in screening for PsA

It should be tested in family investigations

Toronto Psoriatic Arthritis Screening

Questionnaire (ToPAS)

(21)

Acknowledgements

Contribution of all the patients

Support from:

TAS

CIHR

ACE (UHN)

CPSRD

Krembil Foundation

References

Related documents

We conduct Monte Carlo experiments to check the finite sample properties of the 2sQML estimator, and to compare the performance of the estimated diagonal BEKK and diagonal

Texas Southern University, Thurgood Marshall School of Law Houston TX. Texas Tech University School of Law

In healthy non-help seeking students, increased autism traits and increased subclinical psychotic experiences were significantly associated with depressive symptoms; a significant

So far, a dozen of models were developed and executed (simulated), and as a sample, a screenshot of such a model will be presented at the end of the paper. In general, this paper

The paper intends to start with the new angel of media coverage, selecting the firms listed in Shenzhen and Shanghai A-share stock exchanges in the period 2010-2014 as

More specifically, we found that the coachees of professional coaches attended more coaching sessions than peer coachees, reported greater goal progression and environmental

In the second case, market timers do not know the extent to which such strategies are being used but real put options are traded at date 1. In the third case, market timers do

Representative examples of the few tumor biomarkers that have succeeded in reaching routine clinical practice include the HER2 gene amplification and OncotypeDx gene expression